These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 34812901)

  • 21. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
    Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
    Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
    White CM; Weisman N; Dalo J
    Ann Pharmacother; 2023 Sep; 57(9):1062-1075. PubMed ID: 36635883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
    Feulner L; Sermchaiwong T; Rodland N; Galarneau D
    Ochsner J; 2023; 23(4):315-328. PubMed ID: 38143548
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Psychedelics in the treatment of PTSD].
    Vermetten E; Krediet E; Bostoen T; Breeksema JJ; Schoevers RA; van den Brink W
    Tijdschr Psychiatr; 2020; 62(8):640-649. PubMed ID: 32816292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
    de la Salle S; Kettner H; Thibault Lévesque J; Garel N; Dames S; Patchett-Marble R; Rej S; Gloeckler S; Erritzoe D; Carhart-Harris R; Greenway KT
    Sci Rep; 2024 Jul; 14(1):16524. PubMed ID: 39019922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
    Agin-Liebes GI; Malone T; Yalch MM; Mennenga SE; Ponté KL; Guss J; Bossis AP; Grigsby J; Fischer S; Ross S
    J Psychopharmacol; 2020 Feb; 34(2):155-166. PubMed ID: 31916890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review.
    Maia LO; Beaussant Y; Garcia ACM
    J Pain Symptom Manage; 2022 Jun; 63(6):e725-e738. PubMed ID: 35157985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.
    Zia FZ; Baumann MH; Belouin SJ; Dworkin RH; Ghauri MH; Hendricks PS; Henningfield JE; Lanier RK; Ross S; Berger A
    Neuropharmacology; 2023 Aug; 233():109528. PubMed ID: 37015315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
    Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
    ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of psilocybin in depressive disorders.
    Najib J
    Curr Med Res Opin; 2024 Oct; 40(10):1793-1808. PubMed ID: 39177339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.
    Gold ND; Mallard AJ; Hermann JC; Zeifman RJ; Pagni BA; Bogenschutz MP; Ross S
    J Palliat Med; 2023 Oct; 26(10):1408-1418. PubMed ID: 37167080
    [No Abstract]   [Full Text] [Related]  

  • 39. The Potential Role of Serotonergic Hallucinogens in Depression Treatment.
    Psiuk D; Nowak E; Cholewa K; Łopuszańska U; Samardakiewicz M
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440508
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.